Navigation Links
Confirmation of Strong Growth Over the First Half of 2008
Date:8/1/2008

Record Revenue of EUR1.55 Million (+45.5% at Constant Forex)

Substantial Increase in Sales of the JAK2 Test: +169%

LUMINY, France, August 1 /PRNewswire-FirstCall/ -- IPSOGEN (Alternext - FR0010626028 - ALIPS), a pioneer and key player in the development and commercialization of molecular diagnostic tests for cancer, today announces its revenue for its first half to 30 June 2008.

(in thousands of 30 June 2007 30 June 2008 Variation Variation

euros)* at constant

forex

Revenue from products 879 1,415 +,61.2%

Revenue from services 218 137 -37.2%

Consolidated total 1,096 1,552 +41.6% + 45.6%

*non audited data, IFRS For the first half of 2008, revenue totaled EUR1.55 million versus EUR1.09 million for the same period of 2007, an increase of 45.5% at constant forex. At real currency rates, revenue growth was 41.6%.

Sales were up for IPSOGEN's entire portfolio of leukemia tests, but the JAK2 test recorded the most spectacular growth (+169%) despite the fact that this test only obtained CE certification towards the end of the period.

Vincent Fert, President and CEO, states: "We are very pleased with our achievements over this first half. The growth in activity was buoyant and in line with our expectations. These results confirm the potential of the JAK2 test in the diagnosis of myeloproliferative disorders and show that IPSOGEN's product portfolio is perfectly positioned to benefit from the molecular diagnosis of cancer market's very dynamic growth."

About IPSOGEN

IPSOGEN develops and markets molecular diagnostic assays for patients with cancer. With more than 60 products already used routinely in more than 50 countries for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, IPSOGEN is now also targeting breast cancer with the aim of providing diagnostic information that has been inaccessible until now. IPSOGEN intends to establish itself as a world leader in the molecular diagnosis of cancer. The company is pursuing the development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society in general. IPSOGEN has a workforce of some 40 people in France and the United States.

Publication of results for the first half of 2008: 9 October 2008 (after market)


'/>"/>
SOURCE IPSOGEN
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
2. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
3. Strong Demand Pushes up Both Prices and Sales Volumes for Dragons Main Products
4. U-M research: New plastic is strong as steel, transparent
5. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
6. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Cephalon Announces Strong Third Quarter Financial Results
9. Edwards Lifesciences Forecasts Strong Growth in 2008
10. Genoptix Reports Strong Financial Results For Third Quarter 2007
11. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... YORK , Jan. 18, 2017 ... to reach USD 92.9 billion by 2025, according ... Inc. Pharmaceutical industry has been adaptive of the ... as early as 2002. Among the services outsourced, ... forerunners. For instance, Johnson & Johnson was the ...
(Date:1/19/2017)... , Jan. 18, 2017 Acupath Laboratories, Inc., ... the formation of an Executive Committee that will guide ... John Cucci , a 15-year veteran ... Director of Business Development to Chief Sales Officer ... Cucci served in senior sales leadership roles at several ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... interconnect using USB or PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, ... into a compact business-card sized form factor suitable for prototyping, testing, and production-ready ...
(Date:1/18/2017)... --  Boston Biomedical , an industry leader in the ... pathways, will feature data from two clinical studies for ... Gastrointestinal Cancers Symposium, held from January 19-21, in ... is an orally-administered investigational agent designed to inhibit cancer ... cells (CSCs) possess the property of stemness – the ...
Breaking Biology Technology:
(Date:12/20/2016)... 20, 2016 The rising popularity of ... leasing is stoking significant interest in keyless access ... Bluetooth low energy (BLE), biometrics and near-field communication ... wave of wireless technologies in the automotive industry. ... advanced access systems opens the market to specialist ...
(Date:12/16/2016)... DUBLIN , Dec 16, 2016 Research ... Access System Market - Global Forecast to 2021" report to ... ... projected to grow at a CAGR of 14.06% from 2016 to ... 2016, and is projected to reach 854.8 Million by 2021. The ...
(Date:12/15/2016)... ... and Markets has announced the addition of the "Global Military Biometrics ... forecasts the global military biometrics market to grow at a CAGR of ... prepared based on an in-depth market analysis with inputs from industry experts. ... coming years. The report also includes a discussion of the key vendors ...
Breaking Biology News(10 mins):